Professor Packham leads a research group investigating molecular mechanisms controlling proliferation and survival in malignant lymphocytes and developing novel chemical compounds to interfere with key cancer promoting pathways. He has published more than 130 peer-reviewed papers and patents. Graham Packham is also a cofounder of Karus Therapeutics, a University spin-out company involved in the development of novel therapeutics for cancer and inflammatory disease.